IN178919B - - Google Patents

Info

Publication number
IN178919B
IN178919B IN674CA1995A IN178919B IN 178919 B IN178919 B IN 178919B IN 674CA1995 A IN674CA1995 A IN 674CA1995A IN 178919 B IN178919 B IN 178919B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Jeffrey Clayton Baker
Nancy Delores Carter
Bruce Hill Frank
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22990041&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN178919(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IN178919B publication Critical patent/IN178919B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IN674CA1995 1994-06-16 1995-06-14 IN178919B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/260,647 US5504188A (en) 1994-06-16 1994-06-16 Preparation of stable zinc insulin analog crystals

Publications (1)

Publication Number Publication Date
IN178919B true IN178919B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1997-07-19

Family

ID=22990041

Family Applications (1)

Application Number Title Priority Date Filing Date
IN674CA1995 IN178919B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1994-06-16 1995-06-14

Country Status (29)

Country Link
US (1) US5504188A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0692489B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP3595607B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100369951B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1184234C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE233278T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU697794B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9502798A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2151563C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO4410205A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ286066B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69529708T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0692489T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2188637T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI952930A7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUT73495A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL114152A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN178919B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY130551A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO952334L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ272358A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE21896A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL180968B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RO (1) RO113529B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2156257C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI0692489T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW379228B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
YU (1) YU39595A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA954942B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
US5631347A (en) * 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
US5869604A (en) * 1995-11-09 1999-02-09 Georgia Institute Of Technology Crystallization and purification of polypeptides
DE69806582T2 (de) * 1997-03-20 2003-02-13 Novo Nordisk A/S, Bagsvaerd Verfahren zur herstellung eines therapeutischen puders durch copräzipitation von insulin und einem absorptionsverstärker
US6043214A (en) * 1997-03-20 2000-03-28 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
CN1278737A (zh) * 1997-11-12 2001-01-03 阿尔萨公司 减少多肽自结合的方法
RU2205188C2 (ru) 1998-06-30 2003-05-27 Ново Нордиск А/С Затравочные кристаллы для получения пептидов или протеинов
US6956021B1 (en) * 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
IL142011A0 (en) * 1998-10-16 2002-03-10 Novo Nordisk As Stable concentrated insulin preparations for pulmonary delivery
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
US6635617B1 (en) 1998-10-16 2003-10-21 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
UA67798C2 (uk) * 1998-10-16 2004-07-15 Ново Нордіск А/С Препарати інсуліну, які містять ментол, для доставки через легені
US20040214747A1 (en) * 1999-01-06 2004-10-28 Dimarchi Richard Dennis Method for administering monomeric insulin
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
EP1346726A4 (en) * 2000-12-25 2004-09-15 Shiseido Co Ltd Sympathetic-activating perfume composition
JP4489352B2 (ja) * 2001-02-09 2010-06-23 ジェネンテック, インコーポレイテッド Igf−1の結晶化
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US20030068361A1 (en) * 2001-10-09 2003-04-10 Rimona Margalit Liposome-encapsulated insulin formulations
WO2003031432A1 (en) 2001-10-12 2003-04-17 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
US7601688B2 (en) * 2002-06-13 2009-10-13 Biocon Limited Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
EP2239012A3 (en) 2003-04-11 2011-06-15 High Point Pharmaceuticals, LLC Substituted amide derivatives and pharmaceutical uses thereof
CN104826116A (zh) 2003-11-20 2015-08-12 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
CN101027318B (zh) 2004-07-19 2016-05-25 比奥孔有限公司 胰岛素-低聚物共轭物,制剂及其用途
KR20070085227A (ko) * 2004-08-09 2007-08-27 앨리오스 바이오파마 인크. 합성 초글리코실화, 프로테아제 저항성 폴리펩티드 변이체,경구 제제 및 이를 이용한 방법
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
EP2233470B1 (en) 2005-07-04 2011-12-07 High Point Pharmaceuticals, LLC Histamine H3 receptor antagonists
US8106090B2 (en) 2005-07-20 2012-01-31 Eli Lilly And Company 1-amino linked compounds
BRPI0618649A2 (pt) 2005-11-17 2011-09-06 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto
JP5312054B2 (ja) 2006-03-15 2013-10-09 ノボ・ノルデイスク・エー/エス アミリンとインスリンの混合物
ES2388681T3 (es) 2006-03-28 2012-10-17 High Point Pharmaceuticals, Llc Benzotiazoles con actividad de los receptores de histamina H3
US8927015B2 (en) * 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
AU2007244971B2 (en) 2006-04-24 2012-01-19 Eli Lilly And Company Cyclohexyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
SG163547A1 (en) 2006-05-29 2010-08-30 High Point Pharmaceuticals Llc 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
US20110144010A1 (en) 2007-06-01 2011-06-16 Novo Nordisk A/S Spontaneously Dispersible Preconcentrates Including a Peptide Drug in a Solid or Semisolid Carrier
EP2514407A1 (en) 2007-06-01 2012-10-24 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
EP2167032B1 (en) * 2007-06-13 2019-08-07 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
KR101234540B1 (ko) * 2007-10-16 2013-02-19 바이오콘 리미티드 경구 투여가능한 고형 약제학적 조성물 및 그 제조방법
US20090271021A1 (en) * 2008-04-28 2009-10-29 Popp Shane M Execution system for the monitoring and execution of insulin manufacture
JP2012502048A (ja) 2008-09-08 2012-01-26 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼ活性のモジュレーターおよびその使用方法
JP2012506856A (ja) 2008-10-28 2012-03-22 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼのモジュレーターおよびその使用方法
KR20110088575A (ko) 2008-11-21 2011-08-03 하이 포인트 파마슈티칼스, 엘엘씨 아다만틸 벤즈아미드 화합물
CA2750252A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Synthetic conjugates and uses thereof
CN105753965A (zh) 2009-01-28 2016-07-13 斯马特塞尔斯公司 用于受控药物递送的基于缀合物的系统
EP2408808A4 (en) 2009-03-20 2015-05-06 Smartcells Inc TERMINAL-FUNCTIONALIZED CONJUGATES AND THEIR USE
ES2625125T3 (es) * 2009-08-11 2017-07-18 Biocon Limited Procesos cromatográficos
AU2012213432B2 (en) 2011-02-01 2016-10-13 Novo Nordisk A/S Purification of insulin
US10130684B2 (en) 2011-02-03 2018-11-20 Pharmedica Ltd. Oral dissolving films for insulin administration, for treating diabetes
WO2012115641A1 (en) 2011-02-23 2012-08-30 Elona Biotechnologies Lis-pro proinsulin compositions and methods of producing lis-pro insulin analogs therefrom
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
CN102219851B (zh) * 2011-05-09 2012-05-30 甘李药业有限公司 甘精胰岛素结晶的制备方法
JP6735561B2 (ja) 2012-12-03 2020-08-05 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. O−グリコシル化カルボキシ末端部分(ctp)ペプチド系のインスリンおよびインスリン類似体
EP2970124B1 (en) 2013-03-14 2019-05-22 The Board of Trustees of the Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
CN103342746B (zh) * 2013-07-26 2014-07-30 珠海联邦制药股份有限公司 一种制备稳定的门冬胰岛素结晶的方法
US9822158B2 (en) 2013-12-04 2017-11-21 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin
EP2990033A1 (fr) * 2014-08-26 2016-03-02 Carlina Technologies Procédé de préparation de nanoprécipites de peptide ou protéine de faible poids moléculaire
WO2016032869A1 (en) 2014-08-26 2016-03-03 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin or insulin analog compositions
CN104193819B (zh) * 2014-09-03 2017-05-17 韩飞 胰岛素二聚体晶体的合成和保存方法
CN104761632A (zh) * 2015-04-14 2015-07-08 珠海联邦制药股份有限公司 一种地特胰岛素结晶的制备方法及应用
CN106117345B (zh) * 2015-05-05 2020-11-24 宜昌东阳光长江药业股份有限公司 一种制备甘精胰岛素结晶的方法
CN104892749B (zh) * 2015-06-16 2019-02-05 珠海联邦制药股份有限公司 一种德谷胰岛素结晶的制备方法及应用
CN105753966A (zh) * 2016-05-05 2016-07-13 通化东宝药业股份有限公司 一种重组人胰岛素结晶的制备方法
US11413352B2 (en) 2017-12-18 2022-08-16 Merck, Sharp & Dohme LLC Conjugate based systems for controlled insulin delivery
EP3727424A4 (en) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY
JP2023520049A (ja) 2020-03-31 2023-05-15 プロトマー・テクノロジーズ・インコーポレイテッド 隣接ジオールに対する選択的応答性のためのコンジュゲート
PH12023500012A1 (en) 2020-11-19 2024-03-11 Protomer Tech Inc Aromatic boron-containing compounds and insulin analogs
CN113896784B (zh) * 2021-10-18 2024-04-16 合肥天麦生物科技发展有限公司 一种胰岛素结晶的制备方法及其产品
AU2023272483A1 (en) 2022-05-18 2024-12-12 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE515508A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) *
BE533298A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) *
BE533252A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) *
US2143590A (en) * 1936-09-26 1939-01-10 Univ Alberta Insulin preparation and process of producing crystals of insulin
US2626228A (en) * 1945-05-17 1953-01-20 Novo Terapeutisk Labor As Method of producing crystalline insulin
DK78069C (da) * 1952-06-23 1954-09-06 Novo Terapeutisk Labor As Fremgangsmåde til fremstilling af krystallinsk insulin.
US2920104A (en) 1958-07-01 1960-01-05 Vanderbilt Co R T Stabilized solutions of a dithiocarbamate
US3719655A (en) * 1969-12-05 1973-03-06 Lilly Co Eli Process for the crystallization of the ammonium and alkali metal salts in insulin
DE2933946A1 (de) * 1979-08-22 1981-03-12 Hoechst Ag, 6000 Frankfurt Insulinkristallsuspension und verfahren zu ihrer herstellung.
DE3326472A1 (de) * 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DE3327709A1 (de) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US4764592A (en) * 1987-04-23 1988-08-16 Eli Lilly And Company Crystalline human proinsulin and process for its production
DE3717370A1 (de) * 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
JPH03506023A (ja) * 1988-07-20 1991-12-26 ノボ ノルデイスク アクツイエセルスカプ ポリペプチド
WO1990007522A1 (en) * 1988-12-23 1990-07-12 Novo Nordisk A/S Human insulin analogues
NZ232375A (en) 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
PT792290E (pt) * 1993-09-17 2002-01-30 Novo Nordisk As Insulina acilada
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5597893A (en) * 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina

Also Published As

Publication number Publication date
KR960000922A (ko) 1996-01-25
IL114152A (en) 1999-12-31
CO4410205A1 (es) 1997-01-09
TW379228B (en) 2000-01-11
NO952334L (no) 1995-12-18
IL114152A0 (en) 1995-10-31
JPH08169899A (ja) 1996-07-02
FI952930A0 (fi) 1995-06-14
RU95110107A (ru) 1997-05-10
CA2151563A1 (en) 1995-12-17
EP0692489B1 (en) 2003-02-26
AU2168195A (en) 1996-01-04
CN1128271A (zh) 1996-08-07
HUT73495A (en) 1996-08-28
RU2156257C2 (ru) 2000-09-20
CA2151563C (en) 2007-08-07
SI0692489T1 (en) 2003-06-30
YU39595A (sh) 1997-08-22
RO113529B1 (ro) 1998-08-28
ES2188637T3 (es) 2003-07-01
KR100369951B1 (ko) 2003-03-28
EP0692489A1 (en) 1996-01-17
AU697794B2 (en) 1998-10-15
ATE233278T1 (de) 2003-03-15
NO952334D0 (no) 1995-06-13
MY130551A (en) 2007-06-29
CZ286066B6 (cs) 2000-01-12
PL180968B1 (pl) 2001-05-31
BR9502798A (pt) 1996-06-04
CZ154195A3 (en) 1996-02-14
CN1184234C (zh) 2005-01-12
DE69529708D1 (de) 2003-04-03
FI952930L (fi) 1995-12-17
ZA954942B (en) 1996-12-17
JP3595607B2 (ja) 2004-12-02
US5504188A (en) 1996-04-02
PE21896A1 (es) 1996-06-15
DK0692489T3 (da) 2003-03-31
HU9501715D0 (en) 1995-08-28
PL309099A1 (en) 1995-12-27
NZ272358A (en) 1996-12-20
DE69529708T2 (de) 2003-10-16
FI952930A7 (fi) 1995-12-17

Similar Documents

Publication Publication Date Title
TW274166B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW290487B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW271010B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ITRM950658A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR960701530A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP0669395A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP0671407A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW272316B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ITMI952092A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR9509661A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2727344B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW279901B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2725747B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ECSDI940183S (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK40195A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ECSDI940203S (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ECSDI940194S (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN183956B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR7402097U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ECSDI940213S (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN181916B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN179855B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN178590B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN177330B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ECSDI940191S (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)